When Valeant Pharmaceuticals (NYSE: VRX) reported its fourth-quarter and full-year 2016 results in February, there wasn’t much good news to be found. Sales fell in every business segment, and earnings plunged.
When Valeant Pharmaceuticals (NYSE: VRX) reported its fourth-quarter and full-year 2016 results in February, there wasn’t much good news to be found. Sales fell in every business segment, and earnings plunged.